80 GUEST STREET, BOSTON, MA
Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Shareholder votes
Reports First Quarter 2026 Financial Results and Business Highlights
Aura Biosciences, Inc. Enters Underwriting Agreement for Public Offering
Announces CEO Transition as Advances Phase 3 CoMpass Trial Toward Enrollment Completion
Aura Biosciences Enters Stock Repurchase Agreement with Matrix Capital
Annual Report to Security Holders
Investor Presentation
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities